Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 181

1.

Anomalous Topological Active Matter.

Sone K, Ashida Y.

Phys Rev Lett. 2019 Nov 15;123(20):205502. doi: 10.1103/PhysRevLett.123.205502.

PMID:
31809111
2.

Anti-Tumor Effect of Inhibition of DNA Damage Response Proteins, ATM and ATR, in Endometrial Cancer Cells.

Takeuchi M, Tanikawa M, Nagasaka K, Oda K, Kawata Y, Oki S, Agapiti C, Sone K, Miyagawa Y, Hiraike H, Wada-Hiraike O, Kuramoto H, Ayabe T, Osuga Y, Fujii T.

Cancers (Basel). 2019 Dec 1;11(12). pii: E1913. doi: 10.3390/cancers11121913.

3.

Wavelength control method of upstream signals using AMCC in WDM-PON for 5G mobile fronthaul.

Honda K, Nakamura H, Hara K, Sone K, Nakagawa G, Hirose Y, Hoshida T, Terada J.

Opt Express. 2019 Sep 16;27(19):26749-26756. doi: 10.1364/OE.27.026749.

PMID:
31674550
4.

Primary Intraocular Methotrexate-related Lymphoproliferative Disorder in a Patient with Rheumatoid Arthritis Undergoing Long-term Methotrexate Therapy.

Sone K, Usui Y, Fujii K, Goto H.

Ocul Immunol Inflamm. 2019 Oct 28:1-4. doi: 10.1080/09273948.2019.1668428. [Epub ahead of print] No abstract available.

PMID:
31657661
5.

ABCC11 gene polymorphism as a potential predictive biomarker for an oral 5-fluorouracil derivative drug S-1 treatment in non-small cell lung cancer.

Uemura T, Oguri T, Maeno K, Sone K, Takeuchi A, Fukuda S, Kunii E, Takakuwa O, Kanemitsu Y, Ohkubo H, Takemura M, Ito Y, Niimi A.

Cancer Chemother Pharmacol. 2019 Dec;84(6):1229-1239. doi: 10.1007/s00280-019-03959-3. Epub 2019 Sep 17.

PMID:
31529207
6.

Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma.

Makii C, Ikeda Y, Oda K, Uehara Y, Nishijima A, Koso T, Kawata Y, Kashiyama T, Miyasaka A, Sone K, Tanikawa M, Tsuruga T, Mori-Uchino M, Nagasaka K, Matsumoto Y, Wada-Hiraike O, Kawana K, Hasegawa K, Fujiwara K, Aburatani H, Osuga Y, Fujii T.

Gynecol Oncol. 2019 Nov;155(2):331-339. doi: 10.1016/j.ygyno.2019.08.028. Epub 2019 Sep 5.

PMID:
31493899
7.

Interleukin-17 is associated with expression of programmed cell death 1 ligand 1 in ovarian carcinoma.

Aotsuka A, Matsumoto Y, Arimoto T, Kawata A, Ogishima J, Taguchi A, Tanikawa M, Sone K, Mori-Uchino M, Tsuruga T, Oda K, Kawana K, Osuga Y, Fujii T.

Cancer Sci. 2019 Oct;110(10):3068-3078. doi: 10.1111/cas.14174. Epub 2019 Sep 24.

8.

The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation.

Kojima M, Sone K, Oda K, Hamamoto R, Kaneko S, Oki S, Kukita A, Machino H, Honjoh H, Kawata Y, Kashiyama T, Asada K, Tanikawa M, Mori-Uchino M, Tsuruga T, Nagasaka K, Matsumoto Y, Wada-Hiraike O, Osuga Y, Fujii T.

BMC Cancer. 2019 May 15;19(1):455. doi: 10.1186/s12885-019-5638-9.

9.

Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.

Kukita A, Sone K, Oda K, Hamamoto R, Kaneko S, Komatsu M, Wada M, Honjoh H, Kawata Y, Kojima M, Oki S, Sato M, Asada K, Taguchi A, Miyasaka A, Tanikawa M, Nagasaka K, Matsumoto Y, Wada-Hiraike O, Osuga Y, Fujii T.

Biochem Biophys Res Commun. 2019 May 28;513(2):340-346. doi: 10.1016/j.bbrc.2019.03.155. Epub 2019 Apr 4.

PMID:
30955858
10.

Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohort.

Sone K, Oguri T, Uemura T, Takeuchi A, Fukuda S, Takakuwa O, Maeno K, Fukumitsu K, Kanemitsu Y, Ohkubo H, Takemura M, Ito Y, Niimi A.

BMC Cancer. 2019 Mar 19;19(1):246. doi: 10.1186/s12885-019-5438-2.

11.

Activation of Nrf2/Keap1 pathway by oral Dimethylfumarate administration alleviates oxidative stress and age-associated infertility might be delayed in the mouse ovary.

Akino N, Wada-Hiraike O, Isono W, Terao H, Honjo H, Miyamoto Y, Tanikawa M, Sone K, Hirano M, Harada M, Hirata T, Hirota Y, Koga K, Oda K, Fujii T, Osuga Y.

Reprod Biol Endocrinol. 2019 Feb 13;17(1):23. doi: 10.1186/s12958-019-0466-y.

12.

Usefulness of cell-free and concentrated ascites reinfusion therapy in the therapeutic management of advanced ovarian cancer patients with massive ascites.

Kawata Y, Nagasaka K, Matsumoto Y, Oda K, Tanikawa M, Sone K, Mori-Uchino M, Tsuruga T, Arimoto T, Osuga Y, Fujii T.

Int J Clin Oncol. 2019 Apr;24(4):420-427. doi: 10.1007/s10147-018-1371-7. Epub 2018 Nov 24.

PMID:
30474762
13.

Kaempferol, a natural dietary flavonoid, suppresses 17β-estradiol-induced survivin expression and causes apoptotic cell death in endometrial cancer.

Chuwa AH, Sone K, Oda K, Tanikawa M, Kukita A, Kojima M, Oki S, Fukuda T, Takeuchi M, Miyasaka A, Kashiyama T, Ikeda Y, Nagasaka K, Mori-Uchino M, Matsumoto Y, Wada-Hiraike O, Kuramoto H, Kawana K, Osuga Y, Fujii T.

Oncol Lett. 2018 Nov;16(5):6195-6201. doi: 10.3892/ol.2018.9340. Epub 2018 Aug 21.

14.

TTF-1 Expression Predicts the Merit of Additional Antiangiogenic Treatment in Non-squamous Non-small Cell Lung Cancer.

Takeuchi A, Oguri T, Yamashita Y, Sone K, Fukuda S, Takakuwa O, Uemura T, Maeno K, Fukumitsu K, Kanemitsu Y, Ohkubo H, Takemura M, Ito Y, Niimi A.

Anticancer Res. 2018 Sep;38(9):5489-5495. doi: 10.21873/anticanres.12882.

PMID:
30194207
15.

Hypoxia Induces Hypoxia-Inducible Factor 1α and Potential HIF-Responsive Gene Expression in Uterine Leiomyoma.

Ishikawa H, Xu L, Sone K, Kobayashi T, Wang G, Shozu M.

Reprod Sci. 2019 Mar;26(3):428-435. doi: 10.1177/1933719118776793. Epub 2018 May 20.

PMID:
29779471
16.

Blood Vessel Invasion Is a Strong Predictor of Postoperative Recurrence in Endometrial Cancer.

Sato M, Taguchi A, Fukui Y, Kawata A, Taguchi S, Kashiyama T, Eguchi S, Inoue T, Tomio K, Tanikawa M, Sone K, Mori M, Nagasaka K, Adachi K, Ikemura M, Domoto Y, Arimoto T, Oda K, Fukayama M, Osuga Y, Fujii T.

Int J Gynecol Cancer. 2018 Jun;28(5):875-881. doi: 10.1097/IGC.0000000000001262.

PMID:
29664845
17.

GYY4137, an Extended-Release Hydrogen Sulfide Donor, Reduces NMDA-Induced Neuronal Injury in the Murine Retina.

Sone K, Mori A, Sakamoto K, Nakahara T.

Biol Pharm Bull. 2018;41(4):657-660. doi: 10.1248/bpb.b17-01032.

18.

Quantum valence criticality in a correlated metal.

Kuga K, Matsumoto Y, Okawa M, Suzuki S, Tomita T, Sone K, Shimura Y, Sakakibara T, Nishio-Hamane D, Karaki Y, Takata Y, Matsunami M, Eguchi R, Taguchi M, Chainani A, Shin S, Tamasaku K, Nishino Y, Yabashi M, Ishikawa T, Nakatsuji S.

Sci Adv. 2018 Feb 23;4(2):eaao3547. doi: 10.1126/sciadv.aao3547. eCollection 2018 Feb.

19.

Polycystic Ovarian Morphology may be a Positive Prognostic Factor in Patients with Endometrial Cancer who Achieved Complete Remission after Fertility-Sparing Therapy with Progestin

Fukui Y, Taguchi A, Adachi K, Sato M, Kawata A, Tanikawa M, Sone K, Mori M, Nagasaka K, Matsumoto Y, Arimoto T, Oda K, Osuga Y, Fujii T.

Asian Pac J Cancer Prev. 2017 Nov 26;18(11):3111-3116.

20.

Pneumocystis Pneumonia Secondary to Idiopathic CD4+ T-lymphocytopenia: A Comparison of AIDS and Non-AIDS Patients.

Sone K, Muramatsu H, Nakao M, Kagawa Y, Kurokawa R, Sato H, Niimi A.

Intern Med. 2018 Feb 1;57(3):383-386. doi: 10.2169/internalmedicine.8746-16. Epub 2017 Nov 1.

21.

Predictive and Prognostic Value of CYFRA 21-1 for Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs.

Takeuchi A, Oguri T, Sone K, Ito K, Kitamura Y, Inoue Y, Asano T, Fukuda S, Kanemitsu Y, Takakuwa O, Ohkubo H, Takemura M, Maeno K, Ito Y, Niimi A.

Anticancer Res. 2017 Oct;37(10):5771-5776.

PMID:
28982900
22.

Predictive Role of CYFRA21-1 and CEA for Subsequent Docetaxel in Non-small Cell Lung Cancer Patients.

Sone K, Oguri T, Ito K, Kitamura Y, Inoue Y, Takeuchi A, Fukuda S, Takakuwa O, Maeno K, Asano T, Kanemitsu Y, Ohkubo H, Takemura M, Ito Y, Niimi A.

Anticancer Res. 2017 Sep;37(9):5125-5131.

PMID:
28870944
23.

Osimertinib-induced interstitial lung disease in a patient with non-small cell lung cancer pretreated with nivolumab: A case report.

Takakuwa O, Oguri T, Uemura T, Sone K, Fukuda S, Okayama M, Kanemitsu Y, Ohkubo H, Takemura M, Ito Y, Maeno K, Niimi A.

Mol Clin Oncol. 2017 Sep;7(3):383-385. doi: 10.3892/mco.2017.1349. Epub 2017 Jul 25.

24.

[CLINICAL INVESTIGATION OF TUBERCULOSIS PATIENTS IN A GENERAL HOSPITAL LACKING A TUBERCULOSIS WARD IN WESTERN AICHI PREFECTURE.]

Nakao M, Muramatsu H, Sone K, Suzuki Y, Kagawa Y, Kurokawa R, Aoki S, Okawa H, Sato H.

Kekkaku. 2016 May;91(5):489-494. Japanese.

PMID:
28661589
25.

Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.

Oda K, Tanikawa M, Sone K, Mori-Uchino M, Osuga Y, Fujii T.

Int J Clin Oncol. 2017 Aug;22(4):611-618. doi: 10.1007/s10147-017-1137-7. Epub 2017 May 15. Review.

PMID:
28508305
26.

Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer.

Oki S, Sone K, Oda K, Hamamoto R, Ikemura M, Maeda D, Takeuchi M, Tanikawa M, Mori-Uchino M, Nagasaka K, Miyasaka A, Kashiyama T, Ikeda Y, Arimoto T, Kuramoto H, Wada-Hiraike O, Kawana K, Fukayama M, Osuga Y, Fujii T.

Oncotarget. 2017 Jun 20;8(25):40402-40411. doi: 10.18632/oncotarget.16316.

27.

CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy.

Sone K, Oguri T, Nakao M, Kagawa Y, Kurowaka R, Furuta H, Fukuda S, Uemura T, Takakuwa O, Kanemitsu Y, Ohkubo H, Takemura M, Maeno K, Ito Y, Sato H, Muramatsu H, Niimi A.

Anticancer Res. 2017 Feb;37(2):935-939.

PMID:
28179355
28.

A folylpoly-γ-glutamate synthase single nucleotide polymorphism associated with response to pemetrexed treatment combined with platinum for non-small cell lung cancer.

Fukuda S, Oguri T, Kunii E, Sone K, Uemura T, Takakuwa O, Maeno K, Kanemitsu Y, Ohkubo H, Takemura M, Ito Y, Niimi A.

Lung Cancer. 2016 Dec;102:15-20. doi: 10.1016/j.lungcan.2016.10.006. Epub 2016 Oct 19.

PMID:
27987582
29.

Organic cation transporter 6 directly confers resistance to anticancer platinum drugs.

Oguri T, Kunii E, Fukuda S, Sone K, Uemura T, Takakuwa O, Kanemitsu Y, Ohkubo H, Takemura M, Maeno K, Ito Y, Niimi A.

Biomed Rep. 2016 Nov;5(5):639-643. Epub 2016 Oct 4.

30.

Cryptococcus gattii Genotype VGIIa Infection in an Immunocompetent Japanese Patient: A Case Report and Mini-review.

Nakao M, Muramatsu H, Takahashi T, Niwa S, Kagawa Y, Kurokawa R, Sone K, Uozumi Y, Ohkusu M, Kamei K, Koga H.

Intern Med. 2016;55(20):3021-3024. Epub 2016 Oct 15. Review.

31.

MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53.

Makii C, Oda K, Ikeda Y, Sone K, Hasegawa K, Uehara Y, Nishijima A, Asada K, Koso T, Fukuda T, Inaba K, Oki S, Machino H, Kojima M, Kashiyama T, Mori-Uchino M, Arimoto T, Wada-Hiraike O, Kawana K, Yano T, Fujiwara K, Aburatani H, Osuga Y, Fujii T.

Oncotarget. 2016 Nov 15;7(46):75328-75338. doi: 10.18632/oncotarget.12175.

32.

Autophagy inhibition augments resveratrol-induced apoptosis in Ishikawa endometrial cancer cells.

Fukuda T, Oda K, Wada-Hiraike O, Sone K, Inaba K, Ikeda Y, Makii C, Miyasaka A, Kashiyama T, Tanikawa M, Arimoto T, Yano T, Kawana K, Osuga Y, Fujii T.

Oncol Lett. 2016 Oct;12(4):2560-2566. Epub 2016 Aug 8.

33.
34.

Involvement of the Baeyer-Villiger Monooxygenase IfnQ in the Biosynthesis of Isofuranonaphthoquinone Scaffold of JBIR-76 and -77.

Katsuyama Y, Sone K, Satou R, Izumikawa M, Takagi M, Fujie M, Satoh N, Shin-Ya K, Ohnishi Y.

Chembiochem. 2016 Jun 2;17(11):1021-8. doi: 10.1002/cbic.201600095. Epub 2016 May 9.

PMID:
27158812
35.

Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging.

Inaba K, Oda K, Aoki K, Sone K, Ikeda Y, Miyasaka A, Kashiyama T, Fukuda T, Makii C, Arimoto T, Wada-Hiraike O, Kawana K, Yano T, Osuga Y, Fujii T.

Oncotarget. 2016 May 17;7(20):29577-91. doi: 10.18632/oncotarget.8807.

36.

Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies.

Oda K, Ikeda Y, Kashiyama T, Miyasaka A, Inaba K, Fukuda T, Asada K, Sone K, Wada-Hiraike O, Kawana K, Osuga Y, Fujii T.

J Obstet Gynaecol Res. 2016 Jul;42(7):757-62. doi: 10.1111/jog.13018. Epub 2016 Apr 20. Review.

PMID:
27094348
37.

Significance of survivin as a prognostic factor and a therapeutic target in endometrial cancer.

Chuwa AH, Sone K, Oda K, Ikeda Y, Fukuda T, Wada-Hiraike O, Inaba K, Makii C, Takeuchi M, Oki S, Miyasaka A, Kashiyama T, Arimoto T, Kuramoto H, Kawana K, Yano T, Osuga Y, Fujii T.

Gynecol Oncol. 2016 Jun;141(3):564-569. doi: 10.1016/j.ygyno.2016.04.003. Epub 2016 Apr 16.

PMID:
27079211
38.

Measurement of endometrial thickness by transvaginal ultrasonography to predict pathological response to medroxyprogesterone acetate in patients with grade 1 endometrioid adenocarcinoma.

Sato M, Arimoto T, Kawana K, Miyamoto Y, Ikeda Y, Tomio K, Tanikawa M, Sone K, Mori-Uchino M, Tsuruga T, Nagasaka K, Adachi K, Matsumoto Y, Oda K, Osuga Y, Fujii T.

Mol Clin Oncol. 2016 Apr;4(4):492-496. Epub 2016 Jan 28.

39.

SUV420H1 enhances the phosphorylation and transcription of ERK1 in cancer cells.

Vougiouklakis T, Sone K, Saloura V, Cho HS, Suzuki T, Dohmae N, Alachkar H, Nakamura Y, Hamamoto R.

Oncotarget. 2015 Dec 22;6(41):43162-71. doi: 10.18632/oncotarget.6351.

40.

Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy.

Ikeda Y, Oda K, Ishihara H, Wada-Hiraike O, Miyasaka A, Kashiyama T, Inaba K, Fukuda T, Sone K, Matsumoto Y, Arimoto T, Maeda D, Ikemura M, Fukayama M, Kawana K, Yano T, Aoki D, Osuga Y, Fujii T.

Br J Cancer. 2015 Nov 17;113(10):1477-83. doi: 10.1038/bjc.2015.369. Epub 2015 Nov 10.

41.

[DISSEMINATED MYCOBACTERIUM INTRACELLULARE INFECTION IN A PATIENT WITH MYELODYSPLASTIC SYNDROME].

Kagawa Y, Nakao M, Sone K, Aoki S, Sato H, Muramatsu H.

Kekkaku. 2015 Mar;90(3):425-30. Japanese.

PMID:
26477113
42.

Radical hysterectomy with or without para-aortic lymphadenectomy for patients with stage IB2, IIA2, and IIB cervical cancer: outcomes for a series of 308 patients.

Tsuruga T, Fujimoto A, Kawana K, Mori M, Hasumi Y, Kino N, Tomio K, Miura S, Tanikawa M, Sone K, Miyamoto Y, Ikeda Y, Kojima S, Adachi K, Nagasaka K, Matsumoto Y, Arimoto T, Oda K, Nakagawa S, Horie K, Yasugi T, Yokota H, Osuga Y, Fujii T.

Int J Clin Oncol. 2016 Apr;21(2):359-366. doi: 10.1007/s10147-015-0907-3. Epub 2015 Oct 5.

PMID:
26438230
43.

Gel phantom study of a cryosurgical probe with a thermosiphon effect and liquid nitrogen-cooled aluminum thermal storage blocks.

Isoda H, Takehara Y, Fujino H, Sone K, Suzuki T, Tsuzaki Y, Miyazaki K, Fujie M, Sakahara H, Maekawa Y.

Nagoya J Med Sci. 2015 Aug;77(3):399-407.

44.

Elevation of serum surfactant protein-A with exacerbation in canine eosinophilic pneumonia.

Sone K, Akiyoshi H, Hayashi A, Ohashi F.

J Vet Med Sci. 2016 Jan;78(1):143-6. doi: 10.1292/jvms.14-0643. Epub 2015 Aug 21.

45.

Correction: Integrated Copy Number and Expression Analysis Identifies Profiles of Whole-Arm Chromosomal Alterations and Subgroups with Favorable Outcome in Ovarian Clear Cell Carcinomas.

Uehara Y, Oda K, Ikeda Y, Koso T, Tsuji S, Yamamoto S, Asada K, Sone K, Kurikawa R, Makii C, Hagiwara O, Tanikawa M, Maeda D, Hasegawa K, Nakagawa S, Wada-Hiraike O, Kawana K, Fukayama M, Fujiwara K, Yano T, Osuga Y, Fujii T, Aburatani H.

PLoS One. 2015 Jul 6;10(7):e0132751. doi: 10.1371/journal.pone.0132751. eCollection 2015. No abstract available.

46.

Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas.

Uehara Y, Oda K, Ikeda Y, Koso T, Tsuji S, Yamamoto S, Asada K, Sone K, Kurikawa R, Makii C, Hagiwara O, Tanikawa M, Maeda D, Hasegawa K, Nakagawa S, Wada-Hiraike O, Kawana K, Fukayama M, Fujiwara K, Yano T, Osuga Y, Fujii T, Aburatani H.

PLoS One. 2015 Jun 4;10(6):e0128066. doi: 10.1371/journal.pone.0128066. eCollection 2015. Erratum in: PLoS One. 2015;10(7):e0132751.

47.

Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.

Inaba K, Oda K, Ikeda Y, Sone K, Miyasaka A, Kashiyama T, Fukuda T, Uehara Y, Arimoto T, Kuramoto H, Wada-Hiraike O, Kawana K, Yano T, Osuga Y, Fujii T.

Gynecol Oncol. 2015 Aug;138(2):323-31. doi: 10.1016/j.ygyno.2015.05.031. Epub 2015 May 29.

PMID:
26033306
48.

PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-α/VEGF pathway in endometrial cancer.

Miyasaka A, Oda K, Ikeda Y, Sone K, Fukuda T, Inaba K, Makii C, Enomoto A, Hosoya N, Tanikawa M, Uehara Y, Arimoto T, Kuramoto H, Wada-Hiraike O, Miyagawa K, Yano T, Kawana K, Osuga Y, Fujii T.

Gynecol Oncol. 2015 Jul;138(1):174-80. doi: 10.1016/j.ygyno.2015.04.015. Epub 2015 Apr 22.

PMID:
25913131
49.

100-nm-sized magnetic domain reversal by the magneto-electric effect in self-assembled BiFeO3/CoFe2O4 bilayer films.

Sone K, Naganuma H, Ito M, Miyazaki T, Nakajima T, Okamura S.

Sci Rep. 2015 Apr 23;5:9348. doi: 10.1038/srep09348.

50.

The anti-malarial chloroquine suppresses proliferation and overcomes cisplatin resistance of endometrial cancer cells via autophagy inhibition.

Fukuda T, Oda K, Wada-Hiraike O, Sone K, Inaba K, Ikeda Y, Miyasaka A, Kashiyama T, Tanikawa M, Arimoto T, Kuramoto H, Yano T, Kawana K, Osuga Y, Fujii T.

Gynecol Oncol. 2015 Jun;137(3):538-45. doi: 10.1016/j.ygyno.2015.03.053. Epub 2015 Apr 1.

PMID:
25842161

Supplemental Content

Support Center